FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

FDA 규제 화합물

이 화합물은 FDA 승인 또는 규제 대상입니다. 유효한 처방 없이 구매하는 것은 연방법 위반일 수 있습니다. 지역 법규를 확인하세요.

Tirzepatide

Mounjaro / Zepbound

Weight Loss & Metabolic

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.

작용 메커니즘

Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols start at 2.5mg weekly for 4 weeks, escalating through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum of 15mg weekly.

연구 노트

Clinical Research Status

Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023. The SURMOUNT clinical program demonstrated unprecedented weight loss of up to 22.5% at the highest dose in non-diabetic obese adults. Ongoing trials are investigating applications in heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea, and MASH/NASH.

Key Published Findings

The SURPASS-2 trial showed tirzepatide 15mg was superior to semaglutide 1mg for both HbA1c reduction (-2.46% vs -1.86%) and weight loss (-12.4kg vs -6.2kg). SURMOUNT-1 demonstrated that 22.5% of participants on the 15mg dose achieved greater than 25% body weight loss at 72 weeks. The SURMOUNT-4 trial confirmed that weight regain occurs upon discontinuation, with participants regaining approximately 14% of lost weight after stopping treatment.

Safety Profile

The most common adverse events are gastrointestinal: nausea (12-33%), diarrhea (12-21%), and vomiting (5-12%), generally mild-to-moderate and decreasing with continued use. A boxed warning exists for thyroid C-cell tumors based on rodent studies, though human relevance is uncertain. Pancreatitis, gallbladder events, and hypoglycemia (when combined with sulfonylureas or insulin) are less common but clinically significant risks.

Drug Interactions & Contraindications

Tirzepatide slows gastric emptying, potentially affecting absorption of oral medications, particularly oral contraceptives (backup contraception recommended for 4 weeks after initiation or dose increase). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Dose adjustments may be needed for insulin and sulfonylureas to prevent hypoglycemia when used in combination.

Comparison to Related Compounds

Head-to-head data from SURPASS-2 shows tirzepatide's superiority over semaglutide for both weight loss and glycemic control, likely attributable to the additive GIP receptor agonism. Unlike semaglutide which is purely a GLP-1 agonist, tirzepatide's dual mechanism may better preserve lean mass during weight loss based on preliminary body composition data. Retatrutide (Eli Lilly's triple agonist adding glucagon receptor activity) represents the next evolution, showing up to 24.2% weight loss in Phase 2 trials.

Community Observations

Available in escalating doses from 2.5mg to 15mg, with recommended titration over 20+ weeks to minimize GI side effects. Supply constraints have been a persistent issue since launch, with many patients experiencing difficulty obtaining prescriptions. Cost without insurance is approximately $1,000-1,100/month, though manufacturer savings programs and compounding pharmacies have expanded access.

반감기

~5 days

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Room temperature up to 24 months. Protect from light.

재조성된 상태

Refrigerate 2-8C. Use within 21 days.

미국 법적 상태

FDA-approved (Rx only)

또는 알려진 이름으로

MounjaroZepbound

자주 묻는 질문

Tirzepatide란 무엇인가요?

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.

Tirzepatide는 어떻게 작용하나요?

Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.

Tirzepatide의 미국 규제 현황은 어떤가요?

FDA-approved (Rx only)

Tirzepatide의 반감기는 얼마인가요?

~5 days

Tirzepatide의 다른 이름은 무엇인가요?

Mounjaro, Zepbound

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기